These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 24704346)

  • 1. Safety and feasibility of same-day discharge of patients with hepatocellular carcinoma treated with transarterial chemoembolization with drug-eluting beads in a liver transplantation program.
    Nasser F; Cavalcante RN; Galastri FL; de Rezende MB; Felga GG; Travassos FB; De Fina B; Affonso BB
    J Vasc Interv Radiol; 2014 Jul; 25(7):1012-7. PubMed ID: 24704346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization.
    Prajapati HJ; Rafi S; El-Rayes BF; Kauh JS; Kooby DA; Kim HS
    J Vasc Interv Radiol; 2012 Oct; 23(10):1286-93.e1. PubMed ID: 22999748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
    Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
    J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma.
    Kalva SP; Pectasides M; Liu R; Rachamreddy N; Surakanti S; Yeddula K; Ganguli S; Wicky S; Blaszkowsky LS; Zhu AX
    Cardiovasc Intervent Radiol; 2014 Apr; 37(2):381-7. PubMed ID: 23754191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
    Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
    J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
    Prajapati HJ; Dhanasekaran R; El-Rayes BF; Kauh JS; Maithel SK; Chen Z; Kim HS
    J Vasc Interv Radiol; 2013 Mar; 24(3):307-15. PubMed ID: 23375519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
    Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
    AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and nontarget effects of transarterial chemoembolization in bridging of hepatocellular carcinoma patients to liver transplantation: a histopathologic study.
    Stampfl U; Bermejo JL; Sommer CM; Hoffmann K; Weiss KH; Schirmacher P; Schemmer P; Kauczor HU; Richter GM; Radeleff BA; Longerich T
    J Vasc Interv Radiol; 2014 Jul; 25(7):1018-1026.e4. PubMed ID: 24768235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of drug-eluting bead chemoembolization for hepatocellular carcinoma: comparison of small-versus medium-size particles.
    Padia SA; Shivaram G; Bastawrous S; Bhargava P; Vo NJ; Vaidya S; Valji K; Harris WP; Hippe DS; Kogut MJ
    J Vasc Interv Radiol; 2013 Mar; 24(3):301-6. PubMed ID: 23380737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.
    Niessen C; Unterpaintner E; Goessmann H; Schlitt HJ; Mueller-Schilling M; Wohlgemuth WA; Stroszczynski C; Wiggermann P
    J Vasc Interv Radiol; 2014 Feb; 25(2):240-7. PubMed ID: 24291001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.
    Affonso BB; Galastri FL; da Motta Leal Filho JM; Nasser F; Falsarella PM; Cavalcante RN; de Almeida MD; Felga GEG; Valle LGM; Wolosker N
    World J Gastroenterol; 2019 Oct; 25(37):5687-5701. PubMed ID: 31602168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transarterial chemoembolization with drug-eluting beads is effective for the maintenance of the Milan-in status in patients with a small hepatocellular carcinoma.
    Manini MA; Sangiovanni A; Martinetti L; Viganò D; La Mura V; Aghemo A; Iavarone M; Crespi S; Nicolini A; Colombo M
    Liver Transpl; 2015 Oct; 21(10):1259-69. PubMed ID: 26074360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
    Shuster A; Huynh TJ; Rajan DK; Marquez MA; Grant DR; Huynh DC; Jaskolka JD
    J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modified cisplatin-based transcatheter arterial chemoembolization for large hepatocellular carcinoma: multivariate analysis of predictive factors for tumor response and survival in a 163-patient cohort.
    Yoon HM; Kim JH; Kim EJ; Gwon DI; Ko GY; Ko HK
    J Vasc Interv Radiol; 2013 Nov; 24(11):1639-46. PubMed ID: 23962438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial hepatic chemoembolization with 70-150 µm drug-eluting beads: assessment of clinical safety and liver toxicity profile.
    Odisio BC; Ashton A; Yan Y; Wei W; Kaseb A; Wallace MJ; Vauthey JN; Gupta S; Tam AL
    J Vasc Interv Radiol; 2015 Jul; 26(7):965-71. PubMed ID: 25979305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outpatient Transarterial Chemoembolization of Hepatocellular Carcinoma: Review of a Same-Day Discharge Strategy.
    Fritsche MR; Watchmaker JM; Lipnik AJ; Baker JC; Geevarghese S; Banovac F; Omary RA; Brown DB
    J Vasc Interv Radiol; 2018 Apr; 29(4):550-555. PubMed ID: 29478795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma.
    Sacco R; Bargellini I; Bertini M; Bozzi E; Romano A; Petruzzi P; Tumino E; Ginanni B; Federici G; Cioni R; Metrangolo S; Bertoni M; Bresci G; Parisi G; Altomare E; Capria A; Bartolozzi C
    J Vasc Interv Radiol; 2011 Nov; 22(11):1545-52. PubMed ID: 21849247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma.
    Deipolyi AR; Oklu R; Al-Ansari S; Zhu AX; Goyal L; Ganguli S
    J Vasc Interv Radiol; 2015 Apr; 26(4):516-22. PubMed ID: 25704226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation.
    Chapman WC; Majella Doyle MB; Stuart JE; Vachharajani N; Crippin JS; Anderson CD; Lowell JA; Shenoy S; Darcy MD; Brown DB
    Ann Surg; 2008 Oct; 248(4):617-25. PubMed ID: 18936575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with portal vein invasion: safety, efficacy, and prognostic factors.
    Chern MC; Chuang VP; Liang CT; Lin ZH; Kuo TM
    J Vasc Interv Radiol; 2014 Jan; 25(1):32-40. PubMed ID: 24290099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.